Skip to content
Inciteful Med

Treating Rare Lupus: Standard and Emerging Options

Last updated:

Treating rare cutaneous lupus (LEP, LET, BSLE, CHLE) requires strict trigger management like UV and cold protection, alongside specialized medications. While hydroxychloroquine is the standard, emerging treatments like JAK inhibitors and biologics offer new hope for stubborn cases.

Key Takeaways

  • • Strict trigger management, such as aggressive UV protection for LET and gradual rewarming for CHLE, is essential for preventing cutaneous lupus flares.
  • • Hydroxychloroquine is the standard first-line systemic treatment for most cutaneous lupus variants but requires baseline and ongoing eye exams to monitor for retinal toxicity.
  • • Dapsone is highly effective for the blistering seen in Bullous SLE (BSLE), though patients must be screened for G6PD deficiency before starting.
  • • Advanced therapies, including JAK inhibitors and biologics like anifrolumab, provide emerging treatment options for patients whose lupus does not respond to standard medications.

Managing rare forms of cutaneous lupus (CLE) requires a dual approach: protecting the skin from external triggers and calming an overactive immune system from the inside. While first-line treatments are often similar across variants, the rare subtypes—LEP, LET, BSLE, and CHLE—frequently require specialized medications tailored to their unique biology.

Foundation of Care: Trigger Management

For many patients with rare CLE, lifestyle modifications are as critical as medication.

  • Photoprotection (Essential for LET): Lupus Erythematosus Tumidus is extremely sensitive to UV light [1]. Management mandates high-SPF sunscreen (SPF 60+)—preferably mineral-based versions containing zinc oxide or titanium dioxide—along with physical barriers like UV-protective clothing [2][3]. This includes protecting yourself from UV rays through car windows and even certain indoor fluorescent lights.
  • Cold Protection (Essential for CHLE): Chilblain Lupus is triggered by cold and dampness [4]. Keeping hands, feet, and ears consistently warm is the first step in preventing the painful, purple-red lesions characteristic of this variant [5]. Crucially, if your hands get cold, warm them gradually. Rapid rewarming—like running them under hot water or putting them directly on a space heater—can trigger a severe flare.
  • Smoking Cessation: Smoking not only triggers cutaneous lupus flares but directly blocks antimalarial drugs from working effectively [6].

First-Line Medical Treatments

Most patients begin with topical or mild systemic therapies to reduce local inflammation.

  • Topical Therapies: Corticosteroids and Topical Calcineurin Inhibitors (like tacrolimus or pimecrolimus) are used to treat active lesions [7][8]. These are often the first choice for LET and CHLE [9].
  • Antimalarials: Hydroxychloroquine (HCQ) is the “mainstay” systemic treatment for almost all forms of cutaneous lupus, including LEP and LET [10][11]. It helps regulate the immune response and can prevent the disease from progressing [12]. HCQ is a slow-acting drug and often takes several months to reach full effectiveness.
    • Crucial Safety Note: Because HCQ can rarely cause retinal toxicity, you must have a baseline eye exam when starting the medication, followed by regular checkups with an ophthalmologist.
  • Calcium Channel Blockers: For CHLE, doctors may also prescribe Calcium Channel Blockers (CCBs), such as nifedipine, to improve blood flow and prevent the blood vessels in the fingers and toes from spasming [5].

Specialized Treatments for Rare Subtypes

Dapsone for Bullous SLE (BSLE)

Dapsone is remarkably effective for the blistering seen in BSLE, often leading to complete clearing within weeks [13][14].

  • Important Note: Before starting dapsone, you must be tested for G6PD deficiency. Patients with this deficiency can develop severe anemia if they take dapsone [15].
  • Monitoring: Regular blood counts are required to monitor for side effects like hemolytic anemia (the breakdown of red blood cells) [16].

JAK Inhibitors for Chilblain Lupus (CHLE)

For familial cases of CHLE caused by TREX1 mutations, standard treatments often fail. Emerging research shows that JAK inhibitors (like baricitinib or tofacitinib) can “mute” the overactive interferon signal caused by the mutation [17][18]. These medications have shown significant improvement in skin lesions and systemic inflammation in small case series [17][19].

Biologics for Refractory Disease

When standard treatments like HCQ fail, doctors may turn to advanced biologics.

  • Anifrolumab: This is a newer biologic that blocks the Type I Interferon receptor [20]. It has shown success in treating “refractory” (difficult-to-treat) cases of Lupus Profundus (LEP) and LET [21][22].
  • Rituximab: Sometimes used for severe, non-responsive cases of BSLE [23][24].

Treatment Decision Overview

Variant Key Lifestyle Focus First-Line Systemic Advanced Option
LET Strict Sun Protection [1] Hydroxychloroquine [11] Anifrolumab [21]
CHLE Gradual Warming [4] Hydroxychloroquine & CCBs [25] JAK Inhibitors [17]
LEP Avoid Skin Trauma [26] Hydroxychloroquine [10] Anifrolumab [22]
BSLE Systemic Monitoring [27] Dapsone [13] Rituximab [28]

Frequently Asked Questions

How long does hydroxychloroquine take to work for rare skin lupus?
Hydroxychloroquine is a slow-acting medication that helps regulate the immune system. It typically takes several months of consistent daily use to reach its full effectiveness in managing cutaneous lupus.
Why do I need a G6PD test before taking dapsone for Bullous SLE?
Patients with a G6PD enzyme deficiency are at a high risk of developing a severe breakdown of red blood cells (hemolytic anemia) if they take dapsone. Testing beforehand ensures the medication is safe for you to use.
What are the best ways to prevent Chilblain Lupus flares?
Chilblain Lupus is primarily triggered by cold and damp environments. The best prevention strategy is to keep your hands, feet, and ears consistently warm. If your hands get cold, it is critical to warm them gradually, as rapid heating can trigger a severe flare.
Are there new treatments for rare cutaneous lupus that doesn't respond to standard drugs?
Yes, for difficult-to-treat cases that do not respond to antimalarials or topicals, doctors may explore advanced options. These include JAK inhibitors for Chilblain Lupus or biologics like anifrolumab and rituximab for other stubborn subtypes.

Questions for Your Doctor

  • • Given my specific variant (LET, LEP, CHLE, or BSLE), what is the typical timeline for seeing improvement with first-line treatments like hydroxychloroquine?
  • • Should I be tested for the G6PD enzyme before starting dapsone for my bullous symptoms?
  • • Are Janus Kinase (JAK) inhibitors or anifrolumab an option for me if my skin lesions are not responding to antimalarials?
  • • For my Chilblain Lupus, would genetic testing for the TREX1 mutation be helpful for my diagnosis or treatment plan?
  • • How often should I have bloodwork (like CBC or liver function tests) to monitor for side effects from my current medications?

Questions for You

  • • Do you have a strict daily routine for sun protection, including mineral-based sunscreen (zinc/titanium) and UV-protective clothing?
  • • For those with cold-triggered symptoms, have you found specific clothing or lifestyle changes (like keeping hands and feet consistently warm) that reduce your flares?
  • • Have you noticed any new symptoms like shortness of breath, unusual fatigue, or a yellowing of the skin since starting dapsone or other systemic medications?
  • • Are you tracking your flares in a diary to see if they correlate with specific triggers like sunlight, cold, or stress?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Lupus Erythematosus Tumidus as a Distinct Uncommon Subtype of Cutaneous Lupus Erythematosus: A Case Report and Review.

    Camisa C, Papavero V

    Cureus 2024; (16(4)):e59140 doi:10.7759/cureus.59140.

    PMID: 38803774
  2. 2

    Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.

    Foulke G, Helm LA, Clebak KT, Helm M

    FP essentials 2023; (526()):25-36.

    PMID: 36913660
  3. 3

    Cutaneous lupus erythematosus: clinico-pathologic correlation.

    Filotico R, Mastrandrea V

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2018; (153(2)):216-229 doi:10.23736/S0392-0488.18.05929-1.

    PMID: 29368845
  4. 4

    Chilblain lupus: A rare form of cutaneous lupus erythematosus - A case report.

    Perazzolli G, Banchetti E, Melis E, et al.

    SAGE open medical case reports 2026; (14()):2050313X261415591 doi:10.1177/2050313X261415591.

    PMID: 41625144
  5. 5

    Chilblain Lupus with Nail Involvement: A Case Report and a Brief Overview.

    Lambertini M, Vincenzi C, Dika E, La Placa M

    Skin appendage disorders 2018; (5(1)):42-45 doi:10.1159/000488543.

    PMID: 30643780
  6. 6

    Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.

    Arévalo-Bermúdez MDP, Paradela S, Balboa-Barreiro V, Fonseca E

    Lupus 2020; (29(9)):1021-1030 doi:10.1177/0961203320930094.

    PMID: 32539659
  7. 7

    Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.

    Guenther L, Lynde C, Poulin Y

    Journal of cutaneous medicine and surgery 2019; (23(4_suppl)):27S-34S doi:10.1177/1203475419857668.

    PMID: 31476936
  8. 8

    Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes.

    Alshathri AH, Abdellatif RA, Alshathri AH, et al.

    Annals of medicine and surgery (2012) 2025; (87(5)):2880-2888 doi:10.1097/MS9.0000000000003047.

    PMID: 40337382
  9. 9

    Atorvastatin-induced Lupus Erythematosus Tumidus: A Case Report and Literature Review.

    Trčko K, Lukinovič N, Luzar B

    Acta dermatovenerologica Croatica : ADC 2023; (31(3)):125-132.

    PMID: 38439721
  10. 10

    A Diagnostic Pitfall: Lupus Mastitis Presenting Before Diagnosis of Systemic Lupus Erythematosus.

    Mohammed SR, Capildeo K, Davis-King K, Barrow M

    Case reports in rheumatology 2026; (2026()):5593452 doi:10.1155/crrh/5593452.

    PMID: 41716945
  11. 11

    Hydroxychloroquine-induced generalized myopathy in a patient with lupus tumidus: a case report.

    Verdelli A, Massi D, Maio V, et al.

    Dermatology reports 2024; (16(2)):9771 doi:10.4081/dr.2023.9771.

    PMID: 38979520
  12. 12

    Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study.

    La Rotta-Higuera E, Morgado-Carrasco D, Mansilla-Polo M, et al.

    Actas dermo-sifiliograficas 2025; (116(6)):628-632 doi:10.1016/j.ad.2024.02.038.

    PMID: 39947587
  13. 13

    Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases.

    de Risi-Pugliese T, Cohen Aubart F, Haroche J, et al.

    Seminars in arthritis and rheumatism 2018; (48(1)):83-89 doi:10.1016/j.semarthrit.2017.11.003.

    PMID: 29191376
  14. 14

    Bullous Systemic Lupus Erythematosus As the Initial Presentation of Systemic Lupus Erythematosus.

    Kydyralieva C

    Cureus 2025; (17(9)):e93114 doi:10.7759/cureus.93114.

    PMID: 41141000
  15. 15

    Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model.

    Dziewulska KH, Reisz JA, Hay AM, et al.

    The Journal of pharmacology and experimental therapeutics 2023; (386(3)):323-330 doi:10.1124/jpet.123.001634.

    PMID: 37348965
  16. 16

    Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review.

    Ratanapokasatit Y, Seree-Aphinan C, Chanprapaph K

    Clinical, cosmetic and investigational dermatology 2023; (16()):883-890 doi:10.2147/CCID.S403866.

    PMID: 37038449
  17. 17

    Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.

    Zimmermann N, Wolf C, Schwenke R, et al.

    JAMA dermatology 2019; (155(3)):342-346 doi:10.1001/jamadermatol.2018.5077.

    PMID: 30673078
  18. 18

    Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.

    Zhang S, Song J, Yang Y, et al.

    Pediatric rheumatology online journal 2021; (19(1)):1 doi:10.1186/s12969-020-00490-1.

    PMID: 33407657
  19. 19

    Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.

    Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, et al.

    Dermatology and therapy 2021; (11(3)):733-750 doi:10.1007/s13555-021-00517-9.

    PMID: 33856640
  20. 20

    [Pharmacological actions of anifrolumab (Saphnelo®) and clinical trial results as a treatment for systemic lupus erythematosus].

    Ueha T, Kusuda M, Shibata S, et al.

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2022; (157(4)):271-279 doi:10.1254/fpj.22026.

    PMID: 35781459
  21. 21

    Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.

    Bao A, Petri MA, Fava A, Kang J

    Lupus science & medicine 2023; (10(2)) doi:10.1136/lupus-2023-001007.

    PMID: 38114267
  22. 22

    [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.

    Martín-Torregrosa D, Mansilla-Polo M, Morgado-Carrasco D

    Actas dermo-sifiliograficas 2025; (116(1)):T55-T67 doi:10.1016/j.ad.2024.10.008.

    PMID: 39389344
  23. 23

    Successful treatment of bullous lupus with corticosteroids and belimumab: A case report.

    Keshavamurthy C, Fibeger E, Virata A, Bansal P

    Modern rheumatology case reports 2023; (7(1)):52-56 doi:10.1093/mrcr/rxac046.

    PMID: 35538618
  24. 24

    Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin.

    Juhász M, Rogge M, Chen M, et al.

    Pediatric dermatology 2017; (34(1)):e54-e56 doi:10.1111/pde.13015.

    PMID: 27778386
  25. 25

    Severe Ulcerative Perniosis Treated With Abobotulium Toxin.

    Golub S, Foulke G, Helm M

    Journal of drugs in dermatology : JDD 2021; (20(12)):1350-1351 doi:10.36849/jdd.6176.

    PMID: 34898161
  26. 26

    Lupus profundus limited to a site of trauma: Case report and review of the literature.

    Castrillón MA, Murrell DF

    International journal of women's dermatology 2017; (3(2)):117-120 doi:10.1016/j.ijwd.2017.03.002.

    PMID: 28560307
  27. 27

    Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China.

    Qiao L, Zhang B, Zheng W, et al.

    Orphanet journal of rare diseases 2022; (17(1)):290 doi:10.1186/s13023-022-02445-z.

    PMID: 35871005
  28. 28

    Bullous systemic lupus erythematosus successfully treated with rituximab.

    Lowe CD, Brahe CA, Green B, et al.

    Cutis 2019; (103(6)):E5-E7.

    PMID: 31348461

This page is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or dermatologist before starting or stopping any lupus medication or changing your treatment plan.

Stay up to date

Get notified when new research about Rare cutaneous lupus erythematosus is published.

No spam. Unsubscribe anytime.